en ویروس شناسی Virology Research Article Research Article <div style="text-align: justify;"><span style="font-family:Times New Roman;"><span style="font-size:12px;"><b>Background:</b> The ongoing COVID-19 pandemic has raised concerns regarding the safety and efficacy of vaccination in immunocompromised patients, including those with inflammatory bowel disease (IBD). In this study, we aimed to investigate the effect of the Sinopharm anti-COVID-19 vaccine on fecal calprotectin (fCP) levels and clinical symptoms in patients with ulcerative colitis (UC).<br> <b>Methods:</b> A total of 28 patients with UC (8 females and 20 males), with a mean age of 40.8 &plusmn; 9.7 years, were enrolled in the study. Most patients were receiving 5-aminosalicylic acid (5-ASA) agents. All patients received the Sinopharm anti-COVID-19 vaccine. Fecal calprotectin levels and clinical symptoms were assessed at baseline and at 2 and 12 weeks after vaccination. The Lichtiger score and Mayo score were used to evaluate clinical symptoms.<br> <b>Results:</b> No IBD-related adverse events were reported following vaccination. There was no significant difference in fCP levels between baseline and 2 weeks after vaccination. However, a significant decrease in fCP levels was observed at 12 weeks after vaccination compared to baseline and 2 weeks post-vaccination. Similarly, a significant improvement in clinical symptoms was noted at 2 and 12 weeks after vaccination compared to baseline, as evidenced by a reduction in the Lichtiger score. There was no association between vaccination and the clinical bleeding score (Mayo score). None of the other parameters, including location of injury, type of medication, or sex, were associated with fCP levels, Lichtiger score, or Mayo score.<br> <b>Conclusion</b>: The results of this study suggest that the Sinopharm anti-COVID-19 vaccine is safe for patients with IBD and does not lead to exacerbation of UC symptoms.</span></span></div> Inflammatory Bowel Disease, Colitis, Ulcerative, COVID-19, Vaccines, Safety, Fecal calprotectin 39 42 http://mlj.goums.ac.ir/browse.php?a_code=A-10-1888-1&slc_lang=en&sid=1 Babak Tamizifar Babaktamizifar@gmail.com 100319475328460032337 100319475328460032337 No Isfahan Gastroenterology and Hepatology Research Center, Isfahan University of Medical Sciences, Isfahan, Iran Nazila Kassaian NKassaian@gmail.com 100319475328460032338 100319475328460032338 No Nosocomial Infection Research Center, Isfahan University of Medical Sciences, Isfahan, Iran Marzieh Rahimkhorasani M.Rahimkhorasani@gmail.com 100319475328460032339 100319475328460032339 No Infectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences, Isfahan, Iran Hazhir Moradi Hazhir.Moradi@gmail.com 100319475328460032340 100319475328460032340 No Nosocomial Infection Research Center, Isfahan University of Medical Sciences, Isfahan, Iran Somaieh Sabzali 100319475328460032341 100319475328460032341 No Department of Biology, Faculty of Basic Sciences, Lorestan University, Khorramabad, Iran Kiana Shahzamani shahzamani.k@lums.ac.ir 100319475328460032342 100319475328460032342 Yes Hepatitis Research Center, School of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran Peyman Adibi 100319475328460032343 100319475328460032343 No Isfahan Gastroenterology and Hepatology Research Center, Isfahan University of Medical Sciences, Isfahan, Iran